ImmuPharma has provided details of patient recruitment into its pivotal 52-week Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus.
The company has recruited 200 of 293 initially screened patients in 7 countries and 28 sites. Two patients have already safely completed their 12 month dosing regimen.
Top line results are expected in Q1 2018.
Dr. Robert Zimmer, President & Chief Scientific Officer commented: “Thanks to the diligent work performed by Dr. Fanny Valleix, Head of Clinical Research at ImmuPharma in conjunction with Simbec-Orion, our contract research partner, we achieved our goal to complete patient recruitment before the end of 2016.”
Dr. Zimmer also noted that no drug (active or placebo) related serious adverse events have been recorded to date which is consistent with the strong safety profile of Lupuzor shown in our earlier Phase IIb trial.